Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...

Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate ...

Eisai halted Phase 3 development of lorcaserin for Dravet syndrome due to recruitment challenges. The drug was previously ...

AbbVie faced setbacks with emraclidine's dual pivotal trial failures in schizophrenia treatment, impacting their $8.7B ...

Illumina has moved to dismiss a securities lawsuit against the company’s board members over their $8 billion Grail deal, ...

Trump's HHS nominee Robert F. Kennedy Jr., an anti-vaccine advocate calling for stricter pharma oversight, contrasts with ...

EMA's human medicines committee issued positive recommendations for multiple drugs, including Merck's Keytruda and InflaRx's ...

Eyenovia halted Phase 3 trial of atropine-based myopia treatment after data showed it wouldn't meet primary endpoint. CEO ...

Evotec, a drug discoverer facing challenges under CEO Christian Wojczewski, confirmed receiving the unsolicited offer. The ...

Boston Pharmaceuticals succeeded on the two key endpoints for its Phase 2 MASH study, putting the company in contention with ...

Adaptimmune Therapeutics announces 33% workforce reduction and restructuring to save $300 million through 2028. Company halts ...